We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.
- Recent ARQT Stock Price: $24.11
- Yearly Gain for ARQT stock: 11.36%
- Market Cap for ARQT stock: $1.45B
- P/E Ratio for ARQT stock: -5.225
Will ARQT's stock price go up? Is there an accurate ARQT stock forecast available?
TipRanks.com reports that Arcutis Biotherapeutics currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $49.83. The target pricing ranges from a high ARQT forecast of $61.00 down to a low forecast of $43.00. Arcutis Biotherapeutics (ARQT)’s last closing stock price was $24.11 which would put the average price target at 106.68% upside.
In addition, TradingView issued a Sell rating for ARQT stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ARQT stock.
Other analysts covering ARQT include:
- Sean Kim PhD of JonesTrading issued a Buy rating with the price target of $ 43 on 3 weeks ago
- Chris Shibutani of Goldman Sachs issued a Buy rating with the price target of $ 50 on 1 month ago
- Vikram Purohit of Morgan Stanley issued a Buy rating with the price target of $ 45 on 1 month ago
- Unknown Analyst of Truist Financial issued a Buy rating with the price target of $ 50 on 1 month ago
If you are wondering if ARQT is a good stock to buy, here are 3rd party ratings for ARQT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 25% (63 out of 252)
What is the sentiment on the street regarding Arcutis Biotherapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for ARQT stock: Very Bullish
- Blogger Consensus for ARQT stock: Bullish
- Media Buzz for ARQT stock: Medium
- Insider Signal for ARQT stock: Neutral
- Investor Sentiment for ARQT stock: Very Positive
- Hedge Fund signal for ARQT stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ARQT stock including scouring the social networks like ARQT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ARQT stock chart >>
Summary: Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.
- Recent ALT Stock Price: $22.41
- Yearly Gain for ALT stock: 36.40%
- Market Cap for ALT stock: $1.10B
- P/E Ratio for ALT stock: -9.968
Will ALT's stock price go up? Is there an accurate ALT stock forecast available?
TipRanks.com reports that Altimmune currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $32.50. The target pricing ranges from a high ALT forecast of $50.00 down to a low forecast of $25.00. Altimmune (ALT)’s last closing stock price was $22.41 which would put the average price target at 45.02% upside.
In addition, TradingView issued a Buy rating for ALT stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALT stock.
Other analysts covering ALT include:
- Roger Song of Jefferies issued a Buy rating with the price target of $ 35 on 4 days ago
- Mayank Mamtani of B.Riley Financial issued a Buy rating with the price target of $ 26 on 4 days ago
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $ 25 on 5 days ago
- Patrick Trucchio of H.C. Wainwright issued a Buy rating with the price target of $ 50 on 2 weeks ago
If you are wondering if ALT is a good stock to buy, here are 3rd party ratings for ALT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 29% (74 out of 252)
What is the sentiment on the street regarding Altimmune? (Current ratings compiled by TipRanks.com)
- News Sentiment for ALT stock: Very Bullish
- Blogger Consensus for ALT stock: Bullish
- Media Buzz for ALT stock: Medium
- Insider Signal for ALT stock: Positive
- Investor Sentiment for ALT stock: Very Positive
- Hedge Fund signal for ALT stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on ALT stock including scouring the social networks like ALT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ALT stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================